KLOPIDOGREL (Clopidogrel).

     Methyl (+)-( S )-?-( ortho-chlorophenyl) -6,7 - digidro- tieno [3,2-c] pyridine-5 (4 H) acetate.

     Synonym : Plaviks, Plavix.

     The structure is close to tiklopidinu.

     Ingibiruet aggregation of platelets, blocking (irreversibly) binding to receptors adenozindifosfata platelets.

     Rapidly absorbed in the digestive tract, with max of 1 h, T? 8-h; being in the liver biotransformation education active metabolite, presented with urine and faeces.

     Tromboobrazovaniya applied for prevention in patients with IBS (after myocardial infarction), and cerebral atherosclerosis and peripheral vascular diseases.

     According to published data overseas, in patients with atherosclerosis klopidogrel exceeded atsetilsalitsilovuyu acid in the prevention of cardiovascular complications (including deaths, stroke, and myocardial infarction).

     Assign inside adult for 0,075 g (1 tablet) 1 every day (regardless of meal times).

     Antiagregatsionny effect reaches through 4-7 days after the start of treatment and remained 4-10 days.

     Possible side effects, precautions and contraindications such as a tiklopidina.

     Compared with tiklopidinom use klopidogrela posed less risk of complications (especially toxic effects on bone marrow).

     Children and adolescents (under 18) is not appointed (by the lack of adequate monitoring).

     Product : pills to 0,075 g (75 mg) (N. 14, 28).

Materials allowed to copy only with the active hyperlink to the handbook of medicines